Dopamine transporter imaging as an in vivo marker of dopaminergic neurons

Drugs of the Future

Volumn 26, Issue 3, 2001, Pages 271-279

  Booij, J ^a   Reneman, L ^a   Lavalaye, J ^a   Knol, R J J ^a   De Bruin, K ^a   Speelman, J D ^a   Janssen, A G M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ALTROPANE; CARBON 11; COCAINE DERIVATIVE; DOPAMINE TRANSPORTER; IODINE 123; TRACER;

DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG PROTEIN BINDING; HUMAN; IMAGING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0034986302     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.03.858707     Document Type: Review

References (90)

1. PET evaluation of the dopamine system of the human brain
2. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism
3. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders
4. Altered striatal dopamine reuptake site densities in habitually violent and nonviolent alcoholics
5. Relationship between subjective effects of cocaine and dopamine transporter occupancy
6. 11C]WIN-35,428
7. Dopamine transporter density in patients with attention deficit hyperactivity disorder
8. On the presence of 3-hydroxytyramine in brain
9. Dopamine-containing systems in the CNS
10. Parallel organization of functionally segregated circuits linking basal ganglia and cortex
11. The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and amygdala: Evidence for a parallel organization
12. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method
13. 18F]Fluoro-dopa, an analogue of dopa, and its use in direct measurements of storage, degeneration, and turnover of intracerebral dopamine
14. Dopamine visualised in the basal ganglia of living man
15. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography
16. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
17. 11C-nomifensine and positron emission tomography
18. Mapping cocaine binding sites in human and baboon brain in vivo
19. 123I]-2β-Carbomethoxy-3β-(4-iodophenyl)tropane: High affinity SPECT radiotracer of monoamine reuptake sites in brain
20. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease
21. 123I]β-CIT. Binding kinetics in the human brain
22. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1
23. Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters
24. 125]PE2I
25. The dopamine transporter: Immunochemical characterization and localization in brain
26. Immunochemical analysis of dopamine transporter protein in Parkinson's disease
27. 3H-dopamine uptake into rat brain homogenates
28. Cocaine receptors on dopamine transporters are related to self-administration of cocaine
29. The dopamine transporter. Potential involvement in neuropsychiatric disorders
30. Cloning and expression of a cocaine-sensitive rat dopamine transporter
31. Cloning of the cocaine-sensitive bovine dopamine transporter
32. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter
33. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA
34. Neurotransmitter transporters (plus): A promising new gene family
35. Structure and organization of the gene encoding human dopamine transporter
36. Human dopamine transporter gene (DAT1) maps to chromosome 5p 15.3 and displays a VNTR
37. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease
38. IPT: A novel iodinated ligand for the CNS dopamine transporter
39. PET studies on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease
40. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT
41. 123I]IPT and single-photon emission tomography
42. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β- (4-iodophenyl)-nortropane and the first human study with positron emission tomography
43. Exploration of the dopamine transporter: In vitro and in vivo chracterization of a high-affinity and high-specificity iodinated tropane derivative (E)N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β- (4′-methylphenyl)-nortropane (PE2I)
44. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding
45. Compounds affecting the central nervous system. 4.3β-Phenyltropane-2-carboxylic esters and analogs
46. N-omega-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): Radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters
47. 3H]WIN 35,428) in the monkey brain
48. N-substituted analogs of 2β-carbomethoxy-3β-(4′-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain
49. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys
50. 125]RTI-55: In vitro binding and autoradiographic characterization
51. 11C]β-CIT-FP for quantitation of the dopamine transporter
52. Ageing and Parkinson's disease: Substantia nigra regional selectivity
53. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT
54. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET
55. Dopamine transporter imaging with fluorine-18-FPCIT and PET
56. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging
57. 123I]FP-CIT SPET in healthy volunteers
58. Prediction of dopamine transporter binding availability by genotype: A preliminary report
59. Genotype influences in vivo dopamine transporter availability in human striatum
60. Association of attention-deficit disorder and the dopamine transporter gene
61. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases
62. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study
63. Brain dopamine and the syndromes of Parkinson and Huntington
64. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
65. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum
66. Biochemical pathophysiology of Parkinson's disease
67. Parkinson's disease
68. 18F]dopa PET findings in early Parkinson's disease
69. 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease
70. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
71. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease
72. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease
73. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers
74. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
75. Iodine-123-N-ω-fluoropropyl-2βcarbomethoxy-3β- (4-iodophenyl)tropane SPECT in healthy controls and early stage, drug-naive Parkinson's disease
76. 18F]β-CFT, is reduced in early Parkinson's disease
77. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β-CFT binding with positron emission tomography
78. Multiple system atrophy - The nature of the beast
79. Striatonigral-degeneration: A clinicopathological study
80. Multiple system atrophy with autonomic failure. Clinical, histological and neurochemical observations on four cases
81. 18F-dopa PET data
82. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease
83. 123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy
84. 123I]-FP-CIT study group
85. Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers
86. 123I]β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography
87. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease
88. Tremors in early Parkinson's disease
89. 18F-dopa PET study
90. 123I-IPT brain SPECT study in essential tremor and Parkinson's disease